Search research articles
Contact Us
Filters
Showing results (21-30 of 134) with videos related to
Page
of 14
Sort By:
Cancer Research
|
September 10, 2013
Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies?
John Maher, Antonella A Adami
Clinical and Translational Medicine
|
May 11, 2022
3D modelling of γδ T-cell immunotherapy
Caroline M Hull, John Maher
Immunotherapy
|
March 26, 2015
ErbB-targeted CAR T-cell immunotherapy of cancer
Lynsey M Whilding, John Maher
Blood
|
August 1, 2015
TSLPR: a new CAR in the showroom for B-ALL
David Marc Davies, John Maher
Cancer Cell
|
January 8, 2021
Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells
David M Davies, John Maher
Expert Opinion on Biological Therapy
|
May 1, 2019
Novel approaches to promote CAR T-cell function in solid tumors
Caroline M Hull, John Maher
Immunotherapy
|
August 4, 2017
'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors
David E Gilham, John Maher
Cancers
|
February 25, 2023
CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets
John Maher, David M Davies
Archivum Immunologiae Et Therapiae Experimentalis
|
April 8, 2010
Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells
David Marc Davies, John Maher
Best Practice & Research. Clinical Haematology
|
June 19, 2018
Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety
Leena Halim, Adam Ajina, John Maher
Page
of 14
Search research articles
Search
Showing results (21-30 of 134) with videos related to
Sort By:
Page
of 14
Cancer Research
|
September 10, 2013
Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies?
John Maher, Antonella A Adami
Clinical and Translational Medicine
|
May 11, 2022
3D modelling of γδ T-cell immunotherapy
Caroline M Hull, John Maher
Immunotherapy
|
March 26, 2015
ErbB-targeted CAR T-cell immunotherapy of cancer
Lynsey M Whilding, John Maher
Blood
|
August 1, 2015
TSLPR: a new CAR in the showroom for B-ALL
David Marc Davies, John Maher
Cancer Cell
|
January 8, 2021
Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells
David M Davies, John Maher
Expert Opinion on Biological Therapy
|
May 1, 2019
Novel approaches to promote CAR T-cell function in solid tumors
Caroline M Hull, John Maher
Immunotherapy
|
August 4, 2017
'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors
David E Gilham, John Maher
Cancers
|
February 25, 2023
CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets
John Maher, David M Davies
Archivum Immunologiae Et Therapiae Experimentalis
|
April 8, 2010
Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells
David Marc Davies, John Maher
Best Practice & Research. Clinical Haematology
|
June 19, 2018
Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety
Leena Halim, Adam Ajina, John Maher
Page
of 14